What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?

What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?

Some guidelines describe combined use of hydroxychloroquine and lopinavir/ritonavir as one of the treatment alternatives for severe COVID-19, yet this treatment is not preferable. It requires careful consideration of possible interactions with other drugs, monitoring of cardiotoxicity (including QT-...

书目详细资料
Main Authors:	Yu. Yu. Kiselev, V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev
格式:	文件
语言:	Russian
出版:	Izdatelstvo OKI 2020-10-01
丛编:	Качественная клиническая практика
主题:	коронавирус комбинированная терапия гидроксихлорохин лопинавир/ритонавир covid-19 кардиотоксичность гепатотоксичность
在线阅读:	https://www.clinvest.ru/jour/article/view/525

相似书籍

Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention
由: K. B. Mirzaev, et al.
出版: (2020-10-01)

Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel
由: V. A. Otdelenov, et al.
出版: (2020-10-01)

Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19
由: V. A. Otdelenov, et al.
出版: (2020-10-01)

Kombinirovannaya terapiya preparatom Glibomet bol'nykh sakharnym diabetom tipa 2
由: O E Solov'eva, et al.
出版: (2003-03-01)

РАМИПРИЛ В КОМБИНИРОВАННОЙ ТЕРАПИИ ПОЖИЛЫХ БОЛЬНЫХ ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ
出版: (2006-12-01)

Current and future use of remdesivir in patients with COVID-19
由: V. M. Tsvetov, et al.
出版: (2020-10-01)

Otsenka effektivnosti, perenosimosti i bezopasnosti terapii fluvastatinom i fenofibratom u bol'nykh sakharnym diabetom tipa 2 so smeshannoy giperlipidemiey
由: N E Sarano, et al.
出版: (2002-09-01)

Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy
由: V. M. Tsvetov, et al.
出版: (2020-10-01)

Current and future use of dipyridamole in patients with COVID-19
由: I. S. Burashnikova, et al.
出版: (2020-10-01)

Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab
由: K. B. Mirzaev, et al.
出版: (2020-10-01)

Is it possible to use riamilovir to prevent infection and treat COVID-19?
由: V. M. Tsvetov, et al.
出版: (2020-10-01)

Effects of moexipril and estrogen-progesterone combination in women with heart failure and menopausal syndrome
由: Ya. I. Kots, et al.
出版: (2009-06-01)

Current and future use of umifenovir in patients with COVID-19
由: Yu. Yu. Kiselev, et al.
出版: (2020-10-01)

Rationality of routine clinical use of olokizumab in COVID-19
由: V. M. Tsvetov, et al.
出版: (2020-10-01)

Possibilities for the use of tofacitinib in patients with COVID-19
由: A. V. Matveev, et al.
出版: (2020-10-01)

Current and future use of favipiravir in patients with COVID-19
由: A. V. Matveev, et al.
出版: (2020-10-01)

Current and future use of colchicine in patients with COVID-19
由: Yu. Yu. Kiselev, et al.
出版: (2020-10-01)

Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19?
由: Yu. Yu. Kiselev, et al.
出版: (2020-10-01)

Possibility for the use of bromhexine to prevent infection with SARS-CoV-2
由: K. A. Zagorodnikova, et al.
出版: (2020-10-01)

Could canakinumab be used for COVID-19?
由: V. A. Otdelenov, et al.
出版: (2020-10-01)

Dexamethasone use in patients with COVID-19
由: V. A. Otdelenov, et al.
出版: (2020-10-01)

Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis
由: V. M. Tsvetov, et al.
出版: (2020-10-01)

Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm»
由: V. A. Otdelenov, et al.
出版: (2020-10-01)

IEFFICACY OF INDAPAMIDE AND VALSARTAN COMBINED THERAPY PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC DISORDERS
由: G. A. Khamidullaeva, et al.
出版: (2014-12-01)

Rationale for use mefloquine for COVID-19 treatment
由: V. A. Otdelenov, et al.
出版: (2020-10-01)

Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice
由: Yu. Yu. Kiselev, et al.
出版: (2020-10-01)

Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19
由: V. A. Otdelenov, et al.
出版: (2020-10-01)

Assessment of Clinical and Diagnostic Indicators of Cardiovascular Toxicity in Patients with Non-Hodgkin’s Lymphomas in the Course of Programmatic Antitumor Therapy
由: G. R. Gimatdinova, et al.
出版: (2024-04-01)

Влияние типа ацетилирования на частоту гепатотоксичности изониазида у пациентов с впервые выявленным туберкулезом органов дыхания
出版: (2020-11-01)

Possibilities for the use of anakinra in COVID-19
由: V. A. Otdelenov, et al.
出版: (2020-10-01)

Current and future use of vitamin D<sub>3</sub> in patients with COVID-19
由: I. N. Sychev, et al.
出版: (2020-10-01)

Cardiovascular complications of immune checkpoint inhibitors
由: A. A. Kulievа, et al.
出版: (2020-04-01)

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
由: Arabi, YM, et al.
出版: (2021)

Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19
由: B. K. Romanov
出版: (2020-09-01)

Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge
由: A. V. Krykov, et al.
出版: (2020-10-01)

Cell biobank as a necessary infrastructure for the development and implementation of mesenchymal stem cell-based therapy in the treatment of anthracycline-induced cardiotoxicity. Literature review and own data
由: L. Yu. Grivtsova, et al.
出版: (2020-12-01)

A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections
由: Purwati, et al.
出版: (2021-01-01)

Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials
由: Long Ge, et al.
出版: (2022-03-01)

ИЗМЕНЕНИЯ ЭЛЕКТРОКАРДИОГРАФИЧЕСКИХ ПОКАЗАТЕЛЕЙ ДЕПОЛЯРИЗАЦИИ И РЕПОЛЯРИЗАЦИИ НА ФОНЕ ХИМИОТЕРАПИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ ДОКСОРУБИЦИНОМ
由: И. А. Карпуть, et al.
出版: (2024-09-01)

ПОТЕНЦИАЛ ИСПОЛЬЗОВАНИЯ ДИНАМИКИ ЭЛЕКТРОКАРДИОГРАФИЧЕСКИХ ПОКАЗАТЕЛЕЙ ПРИ ВЫЯВЛЕНИИ КАРДИОТОКСИЧНОСТИ ЧЕРЕЗ 12 МЕСЯЦЕВ ПОСЛЕ ОКОНЧАНИЯ ХИМИОТЕРАПИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ ДОКСОРУБИЦИНОМ
由: И. А. Карпуть, et al.
出版: (2024-05-01)